Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney(Université Paris Cité), Roxana Mehran(Mount Sinai Hospital), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Stuart Pocock(London School of Hygiene & Tropical Medicine), Sabato Sorrentino(Magna Graecia University), Gilles Montalescot(Maastricht University Medical Centre), Birgit Vogel(Cardiovascular Institute of the South), Deborah N. Kalkman(Cardiovascular Institute of the South), Salvatore De Rosa(Magna Graecia University), Gennaro Giustino(Cardiovascular Institute of the South), George Dangas(Mount Sinai Hospital), Robert S. Rosenson(Mount Sinai Hospital), Ciro Indolfi(University of Calabria), Anton Camaj(Columbia University Irving Medical Center), Usman Baber(Icahn School of Medicine at Mount Sinai), Bimmer E. Claessen(Columbia University Irving Medical Center)
Cited by 203
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k